Multifunctional mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) is a potential drug target for the treatment of various pathologies. The most discussed is the pathology associated with Alzheimer's disease (AD), where 17β-HSD10 overexpression and its interaction with amyloid-β peptide contribute to mitochondrial dysfunction and neuronal stress. In this work, a series of new benzothiazole-derived 17β-HSD10 inhibitors were designed based on the structure-activity relationship analysis of formerly published inhibitors. A set of enzyme-based and cell-based methods were used to evaluate the inhibitory potency of new compounds, their interaction with the enzyme, and their cytotoxicity. Most compounds exhibited significantly a higher inhibitory potential compared to published benzothiazolyl ureas and good target engagement in a cellular environment accompanied by low cytotoxicity. The best hits displayed mixed-type inhibition with half maximal inhibitory concentration (IC50) values in the nanomolar range for the purified enzyme (3-7, 15) and/or low micromolar IC50 values in the cell-based assay (6, 13-16).

Faculty of Science Department of Chemistry University of Hradec Kralove Rokitanskeho 62 500 03 Hradec Kralove Czech Republic

See more in PubMed

Yang S.-Y.; He X.-Y.; Schulz H. Multiple Functions of Type 10 17β-Hydroxysteroid Dehydrogenase. Trends Endocrinol Metab 2005, 16 (4), 167–175. 10.1016/j.tem.2005.03.006. PubMed DOI

Du Yan S.; Zhu Y.; Stern E. D.; Hwang Y. C.; Hori O.; Ogawa S.; Frosch M. P.; Connolly E. S.; McTaggert R.; Pinsky D. J.; Clarke S.; Stern D. M.; Ramasamy R. Amyloid Beta -Peptide-Binding Alcohol Dehydrogenase Is a Component of the Cellular Response to Nutritional Stress. J. Biol. Chem. 2000, 275 (35), 27100–27109. 10.1016/S0021-9258(19)61485-7. PubMed DOI

Rauschenberger K.; Schöler K.; Sass J. O.; Sauer S.; Djuric Z.; Rumig C.; Wolf N. I.; Okun J. G.; Kölker S.; Schwarz H.; Fischer C.; Grziwa B.; Runz H.; Nümann A.; Shafqat N.; Kavanagh K. L.; Hämmerling G.; Wanders R. J. A.; Shield J. P. H.; Wendel U.; Stern D.; Nawroth P.; Hoffmann G. F.; Bartram C. R.; Arnold B.; Bierhaus A.; Oppermann U.; Steinbeisser H.; Zschocke J. A Non-Enzymatic Function of 17beta-Hydroxysteroid Dehydrogenase Type 10 Is Required for Mitochondrial Integrity and Cell Survival. EMBO Mol. Med. 2010, 2 (2), 51–62. 10.1002/emmm.200900055. PubMed DOI PMC

Tieu K.; Perier C.; Vila M.; Caspersen C.; Zhang H.-P.; Teismann P.; Jackson-Lewis V.; Stern D. M.; Yan S. D.; Przedborski S. L-3-Hydroxyacyl-CoA Dehydrogenase II Protects in a Model of Parkinson’s Disease. Ann. Neurol. 2004, 56 (1), 51–60. 10.1002/ana.20133. PubMed DOI

He X.-Y.; Isaacs C.; Yang S.-Y. Roles of Mitochondrial 17β-Hydroxysteroid Dehydrogenase Type 10 in Alzheimer’s Disease. J. Alzheimers Dis 2018, 62 (2), 665–673. 10.3233/JAD-170974. PubMed DOI

Du Yan S.; Fu J.; Soto C.; Chen X.; Zhu H.; Al-Mohanna F.; Collison K.; Zhu A.; Stern E.; Saido T.; Tohyama M.; Ogawa S.; Roher A.; Stern D. An Intracellular Protein That Binds Amyloid-β Peptide and Mediates Neurotoxicity in Alzheimer’s Disease. Nature 1997, 389 (6652), 689–695. 10.1038/39522. PubMed DOI

Lustbader J. W.; Cirilli M.; Lin C.; Xu H. W.; Takuma K.; Wang N.; Caspersen C.; Chen X.; Pollak S.; Chaney M.; Trinchese F.; Liu S.; Gunn-Moore F.; Lue L.-F.; Walker D. G.; Kuppusamy P.; Zewier Z. L.; Arancio O.; Stern D.; Yan S. S.; Wu H. ABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer’s Disease. Science 2004, 304 (5669), 448–452. 10.1126/science.1091230. PubMed DOI

He X.-Y.; Wegiel J.; Yang S.-Y. Intracellular Oxidation of Allopregnanolone by Human Brain Type 10 17beta-Hydroxysteroid Dehydrogenase. Brain Res. 2005, 1040 (1–2), 29–35. 10.1016/j.brainres.2005.01.022. PubMed DOI

Seo J.-S.; Lee K.-W.; Kim T.-K.; Baek I.-S.; Im J.-Y.; Han P.-L. Behavioral Stress Causes Mitochondrial Dysfunction via ABAD Up-Regulation and Aggravates Plaque Pathology in the Brain of a Mouse Model of Alzheimer Disease. Free Radic Biol. and Med. 2011, 50 (11), 1526–1535. 10.1016/j.freeradbiomed.2011.02.035. PubMed DOI

Yang S.-Y.; He X.-Y.; Miller D. Hydroxysteroid (17β) Dehydrogenase X in Human Health and Disease. Mol. Cell. Endocrinol. 2011, 343 (1–2), 1–6. 10.1016/j.mce.2011.06.011. PubMed DOI

Yang S.-Y.; He X.-Y.; Isaacs C.; Dobkin C.; Miller D.; Philipp M. Roles of 17β-Hydroxysteroid Dehydrogenase Type 10 in Neurodegenerative Disorders. J. Steroid Biochem Mol. Biol. 2014, 143, 460–472. 10.1016/j.jsbmb.2014.07.001. PubMed DOI

Grimm A.; Schmitt K.; Lang U. E.; Mensah-Nyagan A. G.; Eckert A. Improvement of Neuronal Bioenergetics by Neurosteroids: Implications for Age-Related Neurodegenerative Disorders. Biochim. Biophys. Acta 2014, 1842 (12 Pt A), 2427–2438. 10.1016/j.bbadis.2014.09.013. PubMed DOI

Grimm A.; Biliouris E. E.; Lang U. E.; Götz J.; Mensah-Nyagan A. G.; Eckert A. Sex Hormone-Related Neurosteroids Differentially Rescue Bioenergetic Deficits Induced by Amyloid-β or Hyperphosphorylated Tau Protein. Cell. Mol. Life Sci. 2016, 73 (1), 201–215. 10.1007/s00018-015-1988-x. PubMed DOI PMC

Morsy A.; Maddeboina K.; Gao J.; Wang H.; Valdez J.; Dow L. F.; Wang X.; Trippier P. C. Functionalized Allopurinols Targeting Amyloid-Binding Alcohol Dehydrogenase Rescue Aβ-Induced Mitochondrial Dysfunction. ACS Chem. Neurosci. 2022, 13 (14), 2176–2190. 10.1021/acschemneuro.2c00246. PubMed DOI

Vinklarova L.; Schmidt M.; Benek O.; Kuca K.; Gunn-Moore F.; Musilek K. Friend or Enemy? Review of 17β-HSD10 and Its Role in Human Health or Disease. J. Neurochem 2020, 155 (3), 231–249. 10.1111/jnc.15027. PubMed DOI

Kissinger C. R.; Rejto P. A.; Pelletier L. A.; Thomson J. A.; Showalter R. E.; Abreo M. A.; Agree C. S.; Margosiak S.; Meng J. J.; Aust R. M.; Vanderpool D.; Li B.; Tempczyk-Russell A.; Villafranca J. E. Crystal Structure of Human ABAD/HSD10 with a Bound Inhibitor: Implications for Design of Alzheimer’s Disease Therapeutics. J. Mol. Biol. 2004, 342 (3), 943–952. 10.1016/j.jmb.2004.07.071. PubMed DOI

Ayan D.; Maltais R.; Poirier D. Identification of a 17β-Hydroxysteroid Dehydrogenase Type 10 Steroidal Inhibitor: A Tool to Investigate the Role of Type 10 in Alzheimer’s Disease and Prostate Cancer. ChemMedChem. 2012, 7 (7), 1181–1184. 10.1002/cmdc.201200129. PubMed DOI

Boutin S.; Roy J.; Maltais R.; Alata W.; Calon F.; Poirier D. Identification of Steroidal Derivatives Inhibiting the Transformations of Allopregnanolone and Estradiol by 17β-Hydroxysteroid Dehydrogenase Type 10. Bioorg. Med. Chem. Lett. 2018, 28 (22), 3554–3559. 10.1016/j.bmcl.2018.09.031. PubMed DOI

Boutin S.; Maltais R.; Roy J.; Poirier D. Synthesis of 17β-Hydroxysteroid Dehydrogenase Type 10 Steroidal Inhibitors: Selectivity, Metabolic Stability and Enhanced Potency. Eur. J. Med. Chem. 2021, 209, 11290910.1016/j.ejmech.2020.112909. PubMed DOI

Valaasani K.; Sun Q.; Hu G.; Li J.; Du F.; Guo Y.; Carlson E.; Gan X.; Yan S. Identification of Human ABAD Inhibitors for Rescuing Aβ-Mediated Mitochondrial Dysfunction. Curr. Alzheimer Res. 2014, 11 (2), 128–136. 10.2174/1567205011666140130150108. PubMed DOI PMC

Hroch L.; Benek O.; Guest P.; Aitken L.; Soukup O.; Janockova J.; Musil K.; Dohnal V.; Dolezal R.; Kuca K.; Smith T. K.; Gunn-Moore F.; Musilek K. Design, Synthesis and in Vitro Evaluation of Benzothiazole-Based Ureas as Potential ABAD/17β-HSD10 Modulators for Alzheimer’s Disease Treatment. Bioorg. Med. Chem. Lett. 2016, 26 (15), 3675–3678. 10.1016/j.bmcl.2016.05.087. PubMed DOI

Hroch L.; Guest P.; Benek O.; Soukup O.; Janockova J.; Dolezal R.; Kuca K.; Aitken L.; Smith T. K.; Gunn-Moore F.; Zala D.; Ramsay R. R.; Musilek K. Synthesis and Evaluation of Frentizole-Based Indolyl Thiourea Analogues as MAO/ABAD Inhibitors for Alzheimer’s Disease Treatment. Bioorg. Med. Chem. 2017, 25 (3), 1143–1152. 10.1016/j.bmc.2016.12.029. PubMed DOI

Benek O.; Hroch L.; Aitken L.; Dolezal R.; Guest P.; Benkova M.; Soukup O.; Musil K.; Kuca K.; Smith T. K.; Gunn-Moore F.; Musilek K. 6-Benzothiazolyl Ureas, Thioureas and Guanidines Are Potent Inhibitors of ABAD/17β-HSD10 and Potential Drugs for Alzheimer. Med. Chem. 2017, 13 (4), 345–358. 10.2174/1573406413666170109142725. PubMed DOI

Benek O.; Hroch L.; Aitken L.; Gunn-Moore F.; Vinklarova L.; Kuca K.; Perez D. I.; Perez C.; Martinez A.; Fisar Z.; Musilek K. 1-(Benzo[d]Thiazol-2-Yl)-3-Phenylureas as Dual Inhibitors of Casein Kinase 1 and ABAD Enzymes for Treatment of Neurodegenerative Disorders. J. Enzyme Inhib Med. Chem. 2018, 33 (1), 665–670. 10.1080/14756366.2018.1445736. PubMed DOI PMC

Aitken L.; Benek O.; McKelvie B. E.; Hughes R. E.; Hroch L.; Schmidt M.; Major L. L.; Vinklarova L.; Kuca K.; Smith T. K.; Musilek K.; Gunn-Moore F. J. Novel Benzothiazole-Based Ureas as 17β-HSD10 Inhibitors, A Potential Alzheimer’s Disease Treatment. Molecules 2019, 24 (15), 2757.10.3390/molecules24152757. PubMed DOI PMC

Schmidt M.; Benek O.; Vinklarova L.; Hrabinova M.; Zemanova L.; Chribek M.; Kralova V.; Hroch L.; Dolezal R.; Lycka A.; Prchal L.; Jun D.; Aitken L.; Gunn-Moore F.; Kuca K.; Musilek K. Benzothiazolyl Ureas Are Low Micromolar and Uncompetitive Inhibitors of 17β-HSD10 with Implications to Alzheimer’s Disease Treatment. Int. J. Mol. Sci. 2020, 21 (6), E2059.10.3390/ijms21062059. PubMed DOI PMC

Benek O.; Vaskova M.; Miskerikova M.; Schmidt M.; Andrys R.; Rotterova A.; Skarka A.; Hatlapatkova J.; Karasova J. Z.; Medvecky M.; Hroch L.; Vinklarova L.; Fisar Z.; Hroudova J.; Handl J.; Capek J.; Rousar T.; Kobrlova T.; Dolezal R.; Soukup O.; Aitken L.; Gunn-Moore F.; Musilek K. Development of Submicromolar 17β-HSD10 Inhibitors and Their in Vitro and in Vivo Evaluation. Eur. J. Med. Chem. 2023, 258, 11559310.1016/j.ejmech.2023.115593. PubMed DOI

Schmidt M.; Vaskova M.; Rotterova A.; Fiandova P.; Miskerikova M.; Zemanova L.; Benek O.; Musilek K. Physiologically Relevant Fluorescent Assay for Identification of 17β-hydroxysteroid Dehydrogenase Type 10 Inhibitors. J. Neurochem 2023, 167 (2), 15410.1111/jnc.15917. PubMed DOI

Muirhead K. E. A.; Froemming M.; Li X.; Musilek K.; Conway S. J.; Sames D.; Gunn-Moore F. J. (−)-CHANA, a Fluorogenic Probe for Detecting Amyloid Binding Alcohol Dehydrogenase HSD10 Activity in Living Cells. ACS Chem. Biol. 2010, 5 (12), 1105–1114. 10.1021/cb100199m. PubMed DOI

Molecular Operating Environment (MOE), 02 Chemical Computing Group ULC: Montreal, QC, 2022.

Gupta M.; Lee H. J.; Barden C. J.; Weaver D. F. The Blood–Brain Barrier (BBB) Score. J. Med. Chem. 2019, 62 (21), 9824–9836. 10.1021/acs.jmedchem.9b01220. PubMed DOI

Mahadevan S.; Shukla P. S.; Kalyanaraman V. S.; Kumar S. A. The Action of Phenylthiocyanate on Enzymes. FEBS Lett. 1969, 2 (3), 149–153. 10.1016/0014-5793(69)80004-9. PubMed DOI

Breton R.; Housset D.; Mazza C.; Fontecilla-Camps J. C. The Structure of a Complex of Human 17β-Hydroxysteroid Dehydrogenase with Estradiol and NADP+ Identifies Two Principal Targets for the Design of Inhibitors. Structure 1996, 4 (8), 905–915. 10.1016/S0969-2126(96)00098-6. PubMed DOI

Metodieva V.; Smith T.; Gunn-Moore F.. The Mitochondrial Enzyme 17βHSD10 Modulates Ischemic and Amyloid-β-Induced Stress in Primary Mouse Astrocytes. eNeuro 2022, 9 ( (5), ). ENEURO.0040-22.2022.10.1523/ENEURO.0040-22.2022. PubMed DOI PMC